Nymox Pharmaceutical Corporation Stock News

Nymox Pharmaceutical Corp (NYMX) shares closed today at 1.5% above its 52 week low of $0.94, giving the company a market cap of $80M. The stock is currently down 61.5% year-to-date, down 62.3% over the past 12 months, and down 64.3% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 81.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -270.9% The company's stock price performance over the past 12 months lags the peer average by -268.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Nymox Pharmaceutical Corp (NYMX) shares closed 4.6% lower than its previous 52 week low, giving the company a market cap of $85M. The stock is currently down 59.3% year-to-date, down 60.7% over the past 12 months, and down 63.9% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 30.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -265.7% The company's stock price performance over the past 12 months lags the peer average by -263.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

HASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has completed all the Company’s requi

HASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the Company) is pleased to announce that it has completed all the Companys required tasks in preparation for its planned upcoming regulatory submission for Fexapotide Triflutate for the treatment of BPH.

State Street Corp cut its position in Nymox Pharmaceutical Co. (NASDAQ:NYMX) by 95.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,494 shares of the biopharmaceutical companys stock after selling 624,899 shares during the period. State Street Corps holdings in Nymox Pharmaceutical were worth [] The post State Street Corp Has $48,000 Position in Nymox Pharmaceutical Co. (NASDAQ:NYMX) appeared first on ETF Daily News .

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its competitors? We will compare Nymox Pharmaceutical to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk. Analyst Recommendations This is a summary []

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 public companies in the Diagnostic substances industry, but how does it compare to its peers? We will compare Nymox Pharmaceutical to similar businesses based on the strength of its dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation. Insider and Institutional Ownership 2.5% of Nymox Pharmaceutical []

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 public companies in the Diagnostic substances industry, but how does it contrast to its competitors? We will compare Nymox Pharmaceutical to similar companies based on the strength of its profitability, risk, earnings, dividends, analyst recommendations, valuation and institutional ownership. Risk and Volatility Nymox Pharmaceutical has a beta []

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 public companies in the Diagnostic substances industry, but how does it compare to its competitors? We will compare Nymox Pharmaceutical to similar companies based on the strength of its earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Earnings and Valuation This table compares Nymox Pharmaceutical []

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its competitors? We will compare Nymox Pharmaceutical to related companies based on the strength of its risk, institutional ownership, dividends, valuation, profitability, analyst recommendations and earnings. Institutional & Insider Ownership 2.5% of []

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it compare to its rivals? We will compare Nymox Pharmaceutical to similar companies based on the strength of its analyst recommendations, institutional ownership, risk, earnings, valuation, dividends and profitability. Profitability This table compares Nymox Pharmaceutical and its []

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its competitors? We will compare Nymox Pharmaceutical to related companies based on the strength of its earnings, valuation, analyst recommendations, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 2.5% of []

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its competitors? We will compare Nymox Pharmaceutical to similar businesses based on the strength of its risk, valuation, dividends, profitability, analyst recommendations, institutional ownership and earnings. Valuation & Earnings This table compares []

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it contrast to its rivals? We will compare Nymox Pharmaceutical to similar businesses based on the strength of its analyst recommendations, dividends, risk, profitability, valuation, institutional ownership and earnings. Institutional & Insider Ownership 2.5% of Nymox Pharmaceutical []

HASBROUCK HEIGHTS, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today a one-month update to shareholders as a follow